{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T01:58:06Z","timestamp":1782611886280,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,8]]},"DOI":"10.7759\/cureus.11985","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T01:49:40Z","timestamp":1607478580000},"source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of Tacrolimus Versus Clobetasol in the Treatment of Vitiligo"],"prefix":"10.7759","author":[{"given":"Hassan","family":"Mumtaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salwa","family":"Anis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambreen","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masooma","family":"Rubab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayab","family":"Niazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Bahadur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Subhan","family":"Talpur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad A","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehreem","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20142887","article-title":"Segmental vitiligo after infliximab use for rheumatoid arthritis--a case report","volume":"89","author":"Carvalho CL","year":"2014","unstructured":"Carvalho CL, Ortigosa LC. Segmental vitiligo after infliximab use for rheumatoid arthritis--a case report. An Bras Dermatol. 2014, 89:154-6. 10.1590\/abd1806-4841.20142887","journal-title":"An Bras Dermatol"},{"key":"ref2","article-title":"Topical immunomodulators are effective for treatment of vitiligo","volume":"35","author":"Choi CW","year":"2008","unstructured":"Choi CW, Chang SE, Bak H, et al.. Topical immunomodulators are effective for treatment of vitiligo. J Dermatol. 2008, 35:503-7.","journal-title":"J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.08.017","article-title":"High-potency steroid use in children with vitiligo: a retrospective study","volume":"56","author":"Kwinter J","year":"2007","unstructured":"Kwinter J, Pelletier J, Khambalia A, Pope E. High-potency steroid use in children with vitiligo: a retrospective study. J Am Acad Dermatol. 2007, 56:236-41. 10.1016\/j.jaad.2006.08.017","journal-title":"J Am Acad Dermatol"},{"key":"ref4","article-title":"Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo","volume":"48","author":"Xu AE","year":"2009","unstructured":"Xu AE, Zhang DM, Wei XD, Huang B, Lu LJ. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo. Int J Dermatol. 2009, 48:86-90.","journal-title":"Int J Dermatol"},{"key":"ref5","article-title":"Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership","volume":"164","author":"Eleftheriadou V","year":"2011","unstructured":"Eleftheriadou V, Whitton ME, Gawkrodger DJ, et al.. Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership. Br J Dermatol. 2011, 164:530-6.","journal-title":"Br J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.1643","article-title":"Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease","volume":"20","author":"Spritz RA","year":"2010","unstructured":"Spritz RA. Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease. Thyroid. 2010, 20:745-54. 10.1089\/thy.2010.1643","journal-title":"Thyroid"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.02.013","article-title":"Current remedies for vitiligo","volume":"9","author":"Abu Tahir M","year":"2010","unstructured":"Abu Tahir M, Pramod K, Ansari SH, Ali J. Current remedies for vitiligo. Autoimmun Rev. 2010, 9:516-20. 10.1016\/j.autrev.2010.02.013","journal-title":"Autoimmun Rev"},{"key":"ref8","article-title":"Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo","volume":"15","author":"Coskun B","year":"2005","unstructured":"Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol. 2005, 15:88-91.","journal-title":"Eur J Dermatol"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1001\/archderm.1984.01650410073019","article-title":"Vitiligo treated with topical clobetasol propionate","volume":"120","author":"Kumari J","year":"1984","unstructured":"Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol. 1984, 120:631-5.","journal-title":"Arch Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.5.581","article-title":"A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo","volume":"139","author":"Lepe V","year":"2003","unstructured":"Lepe V, Moncada B, Castanedo-Cazares JP, et al.. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003, 139:581-5. 10.1001\/archderm.139.5.581","journal-title":"Arch Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/46730-efficacy-of-tacrolimus-versus-clobetasol-in-the-treatment-of-vitiligo","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:21:54Z","timestamp":1707506514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/46730-efficacy-of-tacrolimus-versus-clobetasol-in-the-treatment-of-vitiligo"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.11985","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,8]]}}}